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Introduction
There is a lack of consensus about the safety of zinc oxide nanoparticles (ZnO NP) applied topically as a transparent and effective broad spectrum ultraviolet filter, with a range of views expressed by regulatory authorities (1-3), consumer groups (4, 5) and in the scientific literature (6) (7) (8) (9) . These safety concerns should be balanced against the potential benefits provided by ZnO NP-containing sunscreens in preventing adverse outcomes resulting from excessive ultraviolet radiation exposure, which include sunburn and photo-allergy due to accelerated skin ageing, immunosuppression and an increased risk of developing skin cancer (10) .
One perception is that ZnO NP and other small inorganic NP currently used in commercially available sunscreens may penetrate deep into the skin and cause a variety of adverse effects (11) . Topically applied NP occasionally reach the viable epidermis (12, 13) and zinc ions have even been found in human blood and urine after topical ZnO NP application (14, 15) , as well as in the SC and upper epidermis of sunburned pig skin (16) . Further, after short-term in vitro exposure above 15 μg.mL -1 , ZnO NP reduce keratinocyte viability (17) . An alternative view (18) , supported by several in vivo human studies, is that ZnO NP topically applied to un-occluded intact human skin penetrate only into the superficial layers of the stratum corneum (SC), with no penetration to the viable epidermis (VE), both in vitro and in vivo (1-3).
There is a clear need to determine the in vivo penetration and local skin safety of ZnO or other NP in humans after topical application under "in-use" conditions. Of particular importance are the ''in-use '' conditions of abrasion and increased skin hydration that are commonly encountered during work, sport and beach activities. The current safety evaluation of ZnO NP applied to skin has focussed on a systemic margin of safety, noting that the body has homeostatic mechanisms to deal with excessive zinc ion (Zn 2+ ) exposure (19) . We are not aware of any in vivo human study evaluating the local safety of ZnO NP applied to the skin under occlusive conditions without or with impaired skin barrier function.
Here we explore the impact of occlusion on the topical penetration and local toxicity of ZnO NP into the viable epidermis of intact and barrier-impaired human skin in vivo.
Materials and methods

ZnO nanoparticles
Uncoated and coated ZnO NP (Z-COTE ® and Z-COTE ® HP1 respectively; BASF, Ludwigshafen, Germany) were re-suspended in caprylic/capric triglyceride (CCT) for application to the skin. Transmission electron microscopy (TEM) was performed on a JEOL 1400 microscope (JEOL Ltd, Tokyo, Japan) operating at 120kV. Images were acquired using a TVIPS F416 CCD camera (TVIPS, Gauting, Germany) and analysed by ImageJ to determine particle sizes.
Application of ZnO NP to the skin of human volunteers
The study was carried out on 10 healthy subjects between the ages 20 to 40 years with undamaged skin and no history of cutaneous disease. Skin was considered undamaged if TEWL was less than 20 g.m prior to administration of the ZnO NP suspensions. All treatments were applied for 6 hours, after which the excess ZnO NP were wiped off using a surgical swab moistened with water.
Multiphoton-FLIM imaging of autofluorescence and ZnO NP in the skin of human volunteers
A DermaInspect ® system (JenLab GmbH, Jena, Germany) was used for multiphoton tomography (MPT) as previously described (21) . The skin was imaged at three depths from the skin surface, corresponding to the SC (~5-10 µm), stratum granulosum (SG; ~15-20 µm) and stratum spinosum (SS; ~25- , and 1, 5 and 10 mg.mL -1 ) on glass slides using bh SPCImage. GraphPad Prism Ver 6.05 (GraphPad Software, Inc., La Jolla, CA) was used to conduct non-linear regression of standard curves.
Data analysis
FLIM data were derived from the fluorescence lifetime decay curves registered in 256 time channels for each pixel using bh SPCImage 5.0 software (23), as previously described (21) .
For autofluorescence metabolic analysis, a distinct region of interest was defined to encapsulate the viable cells within the SG and SS using SPCImage. To visualize, isolate, and measure the level of ZnO NP distributed in the skin and within targeted regions of interest, the baseline value of the decay curve of each pixel was used. These values ('offset' value in bh SPCImage) were pseudocolored in red to create images.
Quantification of ZnO NP
ZnO NP can be identified by their ability to generate a second-harmonic (SHG) signal. By using this SHG signal, high sensitivity quantitation of ZnO can be achieved. However, melanin and keratin also exhibit strong fluorescence signals with a very short fluorescence lifetime component that can be mistaken for ZnO NP SHG emission. ZnO NP can also be identified by their characteristically slow photoluminescence (PL) decay times. To eliminate interference from endogenous fluorophores, it is thus preferable to use the slow PL signal that is at least one order of magnitude longer than any other endogenous skin component. The compromise for achieving higher specificity is that the sensitivity is decreased. The long decay components can be detected by conventional or advanced phosphorescence lifetime imaging (PLIM) techniques (24) .
To identify ZnO NP, we used a novel approach to analyse FLIM data that contain a signature left by long decay components (μs scale) in the recorded fluorescence decay curves (typically ns scale). When excited by laser pulses with an 80 MHz repetition rate, the slow PL for hundreds of excitation pulses accumulates and forms a quasi-continuous background in the recorded decay functions. We used the fact that this background is significantly larger than the background caused by possible incomplete decay of endogenous fluorescence. The amount of background contained in the decay functions can be considered as a 'by-product' of the fitting procedure with SPCImage (25) and can be used as a measure of the amount of ZnO NP present in the tissue. Under the chosen measurement conditions that were kept constant throughout this study, the ZnO NP 'offset'-signal ('offset' parameter within bh SPCImage determines the baseline of the fluorescence decay curve) was adjusted for the cellular autofluorescence which was found to lie between 0 and 5 counts.
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A standard curve was created for uncoated and coated ZnO NP in CCT (50, 100, 500 μg.mL ) using the normalised offset values. FLIM data were analysed and exported using SPCImage to calculate the normalized offset signal, which was used to plot the standard curve. GraphPad Prism was used for non-linear regression of standard curves to generate a line of best fit which were interpolated for unknown background and ZnO NP normalised offset signal measured in the skin.
Validation of ZnO NP penetration using ex vivo human skin
Human epidermal membranes were prepared from freshly excised abdominal skin by a heat separation technique (26) . After tape-stripping the epidermis 20 times to simulate damaged (barrierimpaired) skin, CCT vehicle or uncoated ZnO NP were applied for 6 hours with occlusion and excess material was swabbed off afterwards. Multiphoton imaging of the epidermis was conducted on a Zeiss LSM 710 microscope equipped with a bh SPC-152 TCSPC module, bh GaAsP hybrid detectors (HPM100-40) and a Ti:Sa laser (Spectra-Physics Mai Tai ® ). Excitation was at 800 nm, with the detection band between 400
and 477 nm.
Labile Zn concentrations within the VE after topical application of uncoated ZnO NP were compared with endogenous concentrations in untreated skin. Vehicle (CCT) was applied to intact VE, while ZnO NP in CCT was applied at the standard in vivo dose of 2 mg.cm -2 to both intact and tape-stripped (x20) VE . After 6 hrs, excess material was wiped off and tissue was cryosectioned. The sections were stained with 10 µL of 10 µM Zinpyr-1 (ZP1, Cayman Chemical Co., Ann Arbor MI) for 10 minutes and excess ZP1 was removed with ultrapure water. Images were taken after excitation at 488 nm using an argon laser and the ZP1 signal intensity was detected at 520-560 nm.
MTS assay on biopsy of viable ex vivo skin
Female abdominal skin samples (1 x 1 cm 2 ) were left intact or tape-stripped x 20. Skin was dosed at 2 mg.cm -2 with uncoated ZnO NP (10% in CCT), occluded and placed in a water bath at 35°C ± 0.1°C. After 6 hrs, excess ZnO was removed, 3 mm biopsies were taken (n=3) and the remaining skin was set aside for MPT-FLIM analysis. The biopsies were placed in a 96 well plate and 100 µL MTS stock solution (Cell Titer 96® aqueous one solution assay, Promega) was added to each. After shaking at 150 rpm for 2 hours at 37°C, the biopsies were removed and washed with 1 mL of sterile PBS. Biopsies were minced with surgical scissors and placed in an Eppendorf tube with 200 µL PBS for extraction, done by 60 min soaking followed by 30 min in an ultrasonic bath and centrifugation at 10,000 rpm for 5 minutes (all at ambient temperature and light protected). Absorbance of supernatants was measured at 490 nm on a plate reader.
Statistics
The average fluorescence lifetime was expressed as mean ± 95% confidence intervals. A p-value less than 0.05 was considered as statistically significant. A Kruskal-Wallis test was performed to calculate the statistical differences between groups with a post-hoc Dunn's multiple comparisons test (GraphPad Prism).
Results
Characterisation and quantitation of uncoated and coated ZnO NP applied to in vivo human skin
Representative TEM images and size distribution histograms for uncoated (65.5 ± 35.6 nm) and coated (74.3 ± 32.3 nm) ZnO NP are shown in Supplementary Fig. S1 . Our approach to quantification of ZnO NP in human skin is illustrated in Fig. 1. Fig. 1A ,B shows the offset representation of the long-time component of the photoluminescence emission recorded with the time-correlated single photon counting (TCSPC) technique during femtosecond laser pulsing used to provide a high specificity for ZnO NP in skin. Fig. 2A (top images) shows that the ZnO NP signal is localised within the SC and skin furrows in intact skin, with no detectable penetration into the VE. In barrier-impaired skin, the ZnO NP signal is predominantly aggregated within the furrows, but signals are also observed on or in the exposed SG layer of the VE in 2 out of 5 volunteers when the tape stripping is sufficient to expose the VE (Fig. 2A, bottom images). ZnO NP levels within the furrow ( Fig. 2A) were variable, but >10 mg.mL -1
, within the regions of interest (ROIs) analysed. In the exposed VE of barrier-impaired skin, the concentrations of uncoated and coated ZnO NP within the indicated ROIs ( Fig. 2A , white-dotted squares) were above 10 mg.mL -1 and approximately 5 mg.mL -1 respectively. Fig. 2B shows the estimated levels of ZnO NP, both uncoated 8 (indicated by squares) and coated (indicated by triangles) within the VE based on representative ROIs measured in 5 volunteers for each treatment group. Overall, the mean concentration of uncoated and coated ZnO NP in barrier-impaired skin was 0.60 mg.mL -1 (Range, 0 -1.6) and 1.2 mg.mL -1 (0 -3.2), which were not statistically significantly different (p>0.05) from other treatment groups or controls.
Effect of occlusion on ZnO NP penetration into in vivo intact and barrier-impaired human skin
The impact of occlusion is shown in Fig. 2C . Both uncoated and coated ZnO NP failed to penetrate into the VE of occluded intact human skin, with no detectable levels above the non-specific background. In contrast, uncoated and coated ZnO NP were found in the upper layer of the VE of barrier-impaired occluded skin in 3 out of 5 volunteers. In aggregate, the viable epidermal levels of uncoated and coated ZnO NP in barrier-impaired occluded skin were determined to be 9.6 mg.mL -1 (Range, 0 -22.9) and 8.4 mg.mL -1 (Range, 0 -8.5) respectively (Fig. 2D) . While the mean concentrations of uncoated and coated ZnO-NP were higher in barrier-impaired occluded skin, compared to intact skin, the differences were not statistically significant (p>0.05).
There were no morphological changes apparent in the VE without and with occlusion and without and with barrier impairment (Fig. 3A) . The unbound/bound ratios (a 1 /a 2 ) and the mean lifetimes ( m ) of predominantly NAD(P)H (and to a minor degree, FAD) in SG of the viable epidermis are shown in Fig. 3B and 3C respectively. As indicated in Figs. 3B and 3C, there were no significant differences in a 1 /a 2 or  m between the controls and any treatment of ZnO NP suspensions, with or without occlusion, in intact or barrier-impaired skin. The viable cells immediately below the superficial viable SG cells of those volunteers with tape stripping sufficient for the VE to be exposed to ZnO NP had no significant changes in the free/bound NAD(P)H ratio a 1 /a 2 and the mean lifetime  m compared with controls.
Validation of the lack of ZnO NP penetration and toxicity with ex vivo occluded barrier-impaired human epidermis
To validate our findings from the in vivo study we used freshly excised human skin. Ex vivo z-stack skin imaging confirmed that topically applied ZnO NP did not penetrate into the VE after application to barrier-impaired epidermal membranes ( Supplementary Fig. F2 ). After application of ZnO NP for 6 h to intact and barrier impaired skin no significant increase of labile zinc was found when compared to the controls (Fig.   4 ). In addition, there was no significant change in the metabolic state of the skin when ZnO NP dosed skin was compared to vehicle controls. An MTS assay from the biopsies showed no significant differences in viability when the ZnO NP treated skin (median abs. 0.28) was compared to untreated skin (median abs.
0.29), with the assay validated by a decrease in cell viability (median abs. 0.20) when DMSO was used as a positive control. FLIM images of NAD(P)H within the VE of freshly excised skin also showed that the localized metabolic state of the keratinocytes within the SG did not change upon ZnO NP application, whereas DMSO dosed skin showed an increase in NAD(P)H mean lifetime. The mechanical action of tape stripping led to an increase in NAD(P)H mean lifetime for both ZnO NP treated and its respective vehicle control.
Discussion
This work has focussed on assessing the penetration and effects of ZnO NP applied to in vivo human skin under "in-use" conditions, as regulatory authorities have suggested this data is presently inadequate (1-3). We also addressed the issue raised by the SCCS: "Any cosmetic products containing ZnO particles (nano or non-nano) with coatings that can promote dermal penetration will also be of concern." We ) based on a signal-to-noise ratio of ~10 (27) . We also minimised the effects of out-of-focus emission signals, one of the potential limitations of all imaging, by flattening the skin with a minimal continuous pressure between the coverslip and the skin by taping and sealing the coverslip in place. If this is not done, and pressure is released and reapplied a number of times, it may result in any ZnO NP remaining on the skin surface (and there may be some, even after wiping off before imaging), tending to accumulate unevenly on the glass under the coverslip. Secondly, a gap between the coverslip and the skin may result in out of focus ZnO agglomerates "swimming" through the upper excitation cone of the laser, giving randomly aberrant signals. It is therefore crucial to apply the soft continuous pressure at all times to minimize these disturbing effects.
These results for in vivo human skin using our newer, sensitive detection method for ZnO NP are consistent with our earlier work (21) , suggesting that topically applied coated and uncoated ZnO NP are found only on the skin surface, in the SC and in the furrows of the skin ( Fig. 2A top images) . Similar findings were found with occlusion of both uncoated and coated ZnO NP (Fig. 2B ). These findings for intact skin are in agreement with previous human in vivo ZnO NP penetration studies showing that topically applied NP remain on the skin surface and accumulate within the SC furrows and hair follicles (27, 28) , with little to no observable penetration into the VE (21, 29) after repeated washing with water (30).
Although skin occlusion can greatly increase the penetration of topically applied chemicals (31), there are very few studies which have explored the impact of occlusion on the human in vivo skin penetration of nanoparticles. Here, we showed that occlusion did not enhance the penetration of uncoated or coated ZnO NP into the VE of intact skin in volunteers (Fig. 2) . This is also generally consistent with biopsy results
showing no significant nanoparticle penetration from a combined TiO 2 NP/ZnO NP sunscreen applied to the skin of volunteers for 48 hours (32).
In contrast, after barrier impairment, whilst the ZnO NP signal was predominantly aggregated within the furrows, ZnO NP signals were also observed within the SG layer of the VE in two of the five volunteers after non-occluded application ( Fig. 2A, bottom images) and three of the five volunteers after occluded application (Fig. 2C ). This may be related to the known inter-subject variability in the amount of stratum corneum removed by 20 tape strips, so that the SG may be exposed to varying degrees (33) . Twenty tape strips have been shown to remove approximately 50% of stratum corneum thickness from human volunteers in our laboratory (unpublished data) and by the Lademann group (34). However, it is also clear from histological studies (35) and from the images shown here in Fig. 2 that the stratum corneum may not be removed evenly over the entire treated surface and that tape stripping can leave "islands" of intact skin surrounded by areas in which the VE is exposed. This could occur regardless of the care taken in applying tapes to the skin consistently. In view of this variability, we suggest that the tape stripping pressure used in our earlier work (29) was not sufficient to significantly expose the VE. In any case, however, our in vivo results here are consistent with our ex vivo results showing that ZnO NP penetration was limited to the upper region of the SG, while not actually penetrating the viable cells (Fig. 4) .
The barrier-impaired studies were undertaken in response to general concern amongst authorities and consumer advocacy groups about the lack of investigations of barrier-impaired/sunburned skin. We previously showed that the levels of coated ZnO NP within the VE of skin lesions in patients with psoriasis/atopic dermatitis were similar to normal skin regions after topical application (29) . This present work shows that the specific concerns raised by Faunce that ZnO NP may penetrate into the VE of barriercompromised skin (36) may be justified. However, our in vivo (Fig. 2 ) and ex vivo ( Currently, there are limited data on the local toxicity of ZnO NP applied to the skin. The most recent summary on the scientific opinions of the safety of ZnO NP, referred to as "Zinc Oxide (Nano Form)", focuses on the margin of safety of zinc absorbed into the systemic circulation and notes that the body has efficient homeostatic mechanisms to handle the balance of systemically absorbed zinc (19) . We found in this work that topical application of uncoated and coated ZnO NP, with and without occlusion and to intact and barrier-impaired skin, did not cause local toxicity to the viable epidermal cells, as evidenced by no detectable changes in cellular morphology or fluorescence lifetime properties of the VE (Fig. 3) . Cellular toxicity, via apoptosis, can be clearly measured by MPT-FLIM as it is associated with an increase in the mean fluorescence lifetime of NAD(P)H and the unbound/bound ratio of NAD(P)H (37-42). As ZnO NP associated toxicity is reported to occur via the induction of apoptosis (43) (44) (45) , the absence of autofluorescence FLIM changes associated with apoptosis suggest that "in-use" exposure (in barrier-impaired skin) does not lead to toxicity within a 6 hour time frame.
In their in vivo human studies of ZnO NP sunscreen application under in-use conditions, Gulson et al. reported very small elevations of zinc concentrations in blood and urine (1/1000 th of total zinc) using a 68
Zn enriched ZnO NP formulation, although this was detected over 5 days with repeated applications (14, 15) . One mechanism by which this could occur is penetration of zinc ions, following hydrolysis of ZnO on the skin surface (46) and indeed there is in vivo evidence in rats (47) and humans (48) that zinc ions, applied in both aqueous (48) and oil-based (47, 48) formulations, are able to penetrate the stratum corneum. In the case of the rats, this led to an apparent increase in plasma zinc levels after 8 hours (47), whereas in the humans, increased zinc was detected in tape strips from the upper stratum corneum after 3 hours (48). To our knowledge, there are no published human studies of zinc levels measured in the viable epidermis after zinc ion application in vivo, nor have the effects of Zn 2+ applied under occlusion been reported. Although these mechanisms of hydrolysis and Zn 2+ penetration are both possible in the case of topical ZnO application, our current findings are consistent with our previous observations that a 6h application time does not result in a significant increase of labile zinc within the VE (46) . This is important, given that Zn 2+ ions are implicated in keratinocyte cytotoxicity, albeit in cultured cells in vitro (17) . Our findings may be partly explained by a minimal dissolution of zinc in the organic vehicle, CCT, particularly after the short contact time. No significant localised toxicity was observed after application of ZnO NP to intact and barrier-impaired skin, either in vivo or in freshly excised human skin. A conventional MTS assay that is sensitive to changes in NAD(P)H confirmed that ZnO NP produced no significant changes in tissue viability. The mechanical action of removing 20 tape strips from the skin resulted in an observed mean NAD(P)H lifetime change on ex vivo viable skin although this was not observed in vivo. This finding warrants further investigation to characterise the differences between the use of in vivo and freshly excised skin. lifetimes  m for all volunteers (n=10, mean ± 95%CI) from the stratum granulosum.
